Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs

Area of Science:

• Radiopharmaceutical therapy
• Immunology
• Preclinical and clinical drug development

Background:

• Alpha-particle radiolabeled antibodies are crucial for targeted cancer therapy.
• Accurate measurement of drug immunoreactivity is essential for clinical trial success.
• Traditional live-cell assays can be time-consuming and complex.

Purpose of the Study:

• To develop and validate a rapid, reproducible fixed-cell assay for determining drug immunoreactivity.
• To establish optimal conditions for cell fixation and immunoreactivity assessment.
• To evaluate the suitability of the fixed-cell assay for clinical applications.

Main Methods:

• Identification of optimal cell fixation protocols.
• Development of a fixed-cell immunoreactivity assay.
• Validation of the assay by comparison with traditional methods.
• Application of the assay in clinical trials.

Main Results:

• Optimal conditions for cell fixation and immunoreactivity assay were identified.
• The fixed-cell assay demonstrated rapidity and consistency.
• The assay was successfully validated in clinical trials.
• The fixed-cell assay offers advantages over traditional live-cell assays.

Conclusions:

• A novel fixed-cell assay provides a rapid and reproducible method for assessing drug immunoreactivity.
• This assay can streamline the qualification of drugs for preclinical and clinical studies.
• The validated fixed-cell assay is suitable for use in clinical trials involving alpha-particle radiolabeled antibodies.